Clinical trials: Atopic Dermatitis, Unspecified
Dermatitis, Atopic, Eczema, Atopic
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)
This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial comparing three creams in the treatment of impetiginous eczema: Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and…
- Conditions
- Dermatitis, Atopic, Eczema, Atopic, Skin Diseases, Eczematous
- Trial name
- NCT00671528
- Testing
- Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate), Cream (betamethasone diproprionate and gentamicin), Cream (betamethasone diproprionate)
- Volunteers
- 3 people
- Sponsor
- Organon and Co
Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss…
- Trial name
- PELISTAD-EX2 (NCT05983068)
- Testing
- dupilumab
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sanofi
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled…
- Trial name
- NemoBaby (NCT07660835)
- Testing
- Nemolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Galderma R&D
Atopic Dermatitis, Pruritus
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis.
- Trial name
- NCT04490109
- Testing
- B244, Vehicle
- Where
- 56 sites in United States
- Volunteers
- 547 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT06700499
- Testing
- AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)
- Where
- 50 sites in China
- Volunteers
- 450 people
- Sponsor
- Akeso
Atopic Dermatitis
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately…
- Trial name
- NCT02465606
- Testing
- Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
- Where
- 19 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
Cutivate Lotion HPA Axis Pediatric Study
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
- Trial name
- NCT00546000
- Testing
- Fluticasone propionate 0.05% lotion
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Dermatitis, Atopic
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
- Trial name
- NCT05450198
- Testing
- MK-6194
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Atopic Dermatitis
Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD)
The main purpose of this study is to demonstrate the safety and efficacy of KAM2904 Face Cream and KAM3008 Body Lotion in reducing the symptoms of mild to moderate AD.
- Trial name
- NCT01781663
- Testing
- KAM2904 Face Cream, KAM3008 Body Lotion, petrolatum-based moisturizer
- Where
- Spain
- Volunteers
- 56 people
- Sponsor
- Kamedis Ltd.
Atopic Dermatitis
A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
This is a Phase II, multi-centre, randomised, double-blind, placebo-controlled study in male and female subjects, aged ≥ 12 years with mild/moderate atopic dermatitis and at least moderate pruritus.
- Trial name
- NCT01808157
- Testing
- CT327 ointment
- Where
- United Kingdom
- Volunteers
- 188 people
- Sponsor
- Creabilis SA
Atopic Dermatitis (AD)
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese…
- Trial name
- NCT05959083
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis
- Trial name
- NCT05526222
- Testing
- Jaktinib Hydrochloride Tablet
- Where
- 2 sites in China
- Volunteers
- 443 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity.
- Trial name
- NCT05001139
- Testing
- Relizema ecofoam
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
- Trial name
- ADmirable (NCT05372419)
- Testing
- Lebrikizumab
- Where
- 36 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07767253
- Testing
- 611
- Where
- 5 sites in China
- Volunteers
- 246 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Eczema
Effect of Moisturizing Creams on Skin Barrier Function
This study is a randomized, double-blind, placebo-controlled bilateral study on the effect of moisturizing creams on skin barrier function.
- Trial name
- NCT00771121
- Testing
- urea/lactic acid
- Where
- 2 sites in Sweden
- Sponsor
- ACO Hud Nordic AB
Atopic Dermatitis (AD)
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
This is a single arm, and open-label phase I study
- Trial name
- NCT07329101
- Testing
- VC005
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Dermatitis, Atopic
A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception)…
- Trial name
- NCT04740892
- Testing
- Wash IP, Cream IP
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Atopic Dermatitis
Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema
This three week study will be conducted to determine the safety and efficacy of an over-the-counter (OTC) cream in children with mild to moderate atopic dermatitis.
- Trial name
- NCT01326910
- Testing
- Colloidal Oatmeal, Topical Cream
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.